MedStar Authors catalog › Details for: 21-gene recurrence assay in patients receiving intraoperative radiotherapy: are "favorable" characteristics a surrogate for low recurrence?.
Normal view MARC view ISBD view

21-gene recurrence assay in patients receiving intraoperative radiotherapy: are "favorable" characteristics a surrogate for low recurrence?.

by Wehner, Patricia; Mete, Mihriye; Zhao, Danjing.
Citation: Gland Surgery. 6(6):675-681, 2017 Dec.Journal: Gland surgery.Published: 2017ISSN: 2227-684X.Full author list: Oppong BA; Sen Gupta S; Gary M; Wehner P; Mete M; Zhao D; Seevaratnam S; Rudra S; Willey SC.UI/PMID: 29302485.Subject(s): IN PROCESS -- NOT YET INDEXEDInstitution(s): MedStar Health Research Institute | Washington Cancer InstituteActivity type: Journal Article.Medline article type(s): Journal ArticleOnline resources: Click here to access online Digital Object Identifier: https://dx.doi.org/10.21037/gs.2017.07.05 (Click here) Abbreviated citation: Gland surg.. 6(6):675-681, 2017 Dec.Abstract: Background: Intraoperative radiotherapy (IORT) has gained momentum for early stage and favorable breast cancers (BC). The 21-gene recurrence assay guides treatment of hormone positive and node-negative BC.Abstract: Methods: Analysis of 82 invasive BC treated with breast conservation surgery (BCS) and IORT 2013-2015. Data collection included patient demographics, tumor characteristics, nodal status, recurrence test (RS) and adjuvant therapy.Abstract: Results: The mean age was 68 years. Tumors were stage Ia (86.6%), 3.6% Ib and 9.8% IIa. Of 50 patients (61.0%) with RS testing, 72% (n=36) were low risk (RS 0-17), with 28% (n=14) at intermediate risk (RS 18-30). The 39% (n=32) of patients without RS testing, were more likely to have smaller tumors (1.3 vs. 0.9 cm) and age >70 (P<0.05).Abstract: Conclusions: Most patients selected for IORT based on clinical features were indeed low risk based on RS. Given the limited long-term clinical outcome and safety data of this technique, additional investigation is needed.

Powered by Koha